Consensus Amgen Inc. Xetra

Stocks

AMG

US0311621009

Pharmaceuticals

Market Closed - Xetra 11:35:30 2026-09-11 EDT			5-day change	1st Jan Change
327.30 ^EUR	-0.79%		-13.13%	+16.77%

09-11	Dublin residents have mixed feelings ahead of Trump visit to Ireland	RE
09-10	Amgen Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-10-2026 11:00 AM

03ff883e06fad75e3139a17e.d6tXJdap2gHVPkc3vWDHeTvWb1Nq3vI9yswi3KWFrug.I-Q_VKLY6HmQdDQB1S3qT16CVgMclJdNvrZvuujgwb0d6gRQj-WIOeBsNA~d1c2776f7a91b199498beb33af59aa25

Analysts' recommendations: Amgen Inc.

09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
09-08	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
09-08	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
09-07	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
09-04	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
08-10	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
08-07	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
08-06	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
08-05	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
08-05	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
08-05	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
08-05	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
08-05	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT
08-05	TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating	MT
08-05	Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+18.19%
	JOHNSON & JOHNSON					+4.64%
	ABBVIE INC.					+7.85%
	ROCHE HOLDING AG					+8.57%
	NOVARTIS AG					+11.68%
	ASTRAZENECA PLC					+34.09%
	AMGEN INC.					+2.83%
	NOVO NORDISK A/S					+12.2%
	GILEAD SCIENCES, INC.					+10.04%
	Average					+12.23%
	Weighted average by Cap.					+12.45%